Know Cancer

forgot password

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

Phase 2
18 Years
Not Enrolling
Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer

Thank you

Trial Information

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

Treatment - If you take part in this trial you will be treated for about 10 weeks. You will
receive an injection of Allovectin-7® by needle, directly into one or more selected tumors
once a week for the first six weeks. The injections may be given in a doctor's office.
During a four-week observation period, your disease will be measured to see if the treatment
is working. This will be done by general physical exams and scans (such as X-ray scans).
Patients who show no sign of disease progression may be offered an option to repeat this
treatment course.

Inclusion Criteria

In order to be in this trial, you must meet the enrollment criteria. Below is a list of
some of the enrollment criteria.

- You have been diagnosed with Stage III or Stage IV melanoma

- Your cancer has returned after a prior treatment (e.g. radiation or chemotherapy) or
you refused therapy with standard treatment

- You are able to carry out your normal daily activities

- Your melanoma has not spread to your brain

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

February 2001

Completion Date:

September 2004

Related Keywords:

  • Melanoma
  • Metastatic Melanoma
  • Malignant Melanoma
  • Skin Cancer
  • Melanoma
  • Metastatic Melanoma
  • Malignant Melanoma
  • Skin Cancer
  • Tumor
  • Experimental Treatment
  • Clinical Trial
  • Gene Therapy
  • Gene Delivery
  • Gene Transfer
  • Immunotherapy
  • Cancer
  • Neoplasm
  • Lesion
  • Metastasis
  • Cancerous mole
  • Melanoma vaccine
  • Cancer research
  • Cancer cells
  • Allovectin-7®
  • Skin Neoplasms
  • Melanoma



Arizona Cancer Center Tucson, Arizona  85724
MD Anderson Cancer Center Houston, Texas  77030-4096
Mayo Clinic Rochester, Minnesota  55905
University of Colorado Cancer Center Denver, Colorado  80262
Beth Israel Medical Center New York, New York  10003
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire  03756
Comprehensive Blood and Cancer Center Bakersfield, California  93309
North Memorial Health Care Robbinsdale, Minnesota  55422
Louisiana State University Medical Center Lafayette, Louisiana  70502-4016
University of California, San Francisco San Francisco, California  94143
Duke University Medical Center Durham, North Carolina  27710
University of Arkansas Cancer Research Center Little Rock, Arkansas  72205
Oncology Specialists, S.C. Park Ridge, Illinois  60068
Hematology Oncology Associates of Baltimore Baltimore, Maryland  21236
The Melanoma Center of Saint Louis Saint Louis, Missouri  63131
Cancer Care Alliance Seattle, Washington  98109